Entacapone: Uses, Dosage, Side Effects, and Interactions

Entacapone is a prescription medication used alongside levodopa/carbidopa to treat Parkinson’s disease, specifically to stretch out the time each levodopa dose keeps symptoms under control. It works by blocking an enzyme that breaks down levodopa before it reaches the brain, and it has become one of the most commonly prescribed add-on treatments for people whose levodopa doses start wearing off too soon. The drug has a well-studied safety profile spanning more than two decades, though it comes with a handful of side effects worth understanding before you start.

How Entacapone Works

Levodopa is the gold-standard treatment for Parkinson’s disease, but your body is remarkably efficient at breaking it down before it does any good. One of the enzymes responsible for this breakdown is called COMT (catechol-O-methyltransferase). COMT converts levodopa into a metabolite called 3-O-methyldopa, which cannot cross from the bloodstream into the brain. Entacapone blocks this enzyme in the bloodstream, preventing that conversion and allowing more levodopa to reach the brain where it is needed.¹

Carbidopa, the other drug in the standard levodopa combination, blocks a different enzyme (called AADC) that also degrades levodopa before it reaches the brain. So when you take all three together, two separate breakdown pathways are shut down simultaneously, and significantly more levodopa survives the trip to the brain.² Entacapone works only in the bloodstream and peripheral tissues; it does not enter the brain itself. This matters because it means the drug enhances levodopa delivery without directly altering brain chemistry on its own.

Who Benefits From Entacapone

Entacapone is approved as an add-on to levodopa/carbidopa therapy. It is not a standalone treatment for Parkinson’s disease and has no effect without levodopa on board. The clearest benefit is for people experiencing what neurologists call “wearing off,” where a dose of levodopa stops controlling symptoms before the next dose is due, leaving stretches of the day when tremor, stiffness, or slowness come back.

In a well-known six-month trial, patients taking entacapone alongside levodopa gained roughly an extra hour and a half of symptom-free (“on”) time per day, rising from about 9.3 hours to 10.7 hours. Their “off” time dropped correspondingly. Patients were also able to lower their daily levodopa dose by about 100 mg on average.³ A separate trial in both fluctuating and non-fluctuating patients found a similar pattern: on-time increased from about 9.5 to 10.8 hours per day, with off-time dropping by roughly an hour, all while patients needed less levodopa.⁴

That second trial is worth noting because it showed benefit even in people who had not yet developed obvious wearing-off symptoms, suggesting the drug can help smooth levodopa delivery before fluctuations become severe. In practice, though, most doctors prescribe entacapone once wearing off has clearly begun.

Dosage and How to Take It

Entacapone is taken with every dose of levodopa/carbidopa. The standard tablet is 200 mg, and it is swallowed at the same time as each levodopa dose throughout the day.⁵ Because people with Parkinson’s may take levodopa anywhere from three to eight or more times per day, the total daily entacapone dose varies. The maximum recommended amount is 2,000 mg per day, meaning up to ten doses.⁶

Because entacapone makes each levodopa dose more potent, your doctor will often need to reduce your levodopa strength after starting entacapone. This is not a sign that something is wrong; it reflects the fact that more levodopa is now getting through. Failing to adjust the levodopa dose is one of the main reasons people experience side effects like involuntary movements (dyskinesia) early in treatment.

Entacapone is also available as a fixed-dose combination tablet called Stalevo, which bundles levodopa, carbidopa, and entacapone into a single pill. This simplifies the regimen, which matters more than it might sound. In a large adherence study, patients taking the combined tablet were dramatically more likely to stick with their regimen compared to patients juggling separate pills. Non-adherence dropped by about 79%, and the odds of unsatisfactory adherence fell by 86%.⁷ When you are already taking multiple medications throughout the day, reducing the pill count matters for real-world outcomes.

Common Side Effects

Most of entacapone’s side effects fall into two buckets: effects that come from boosting levodopa’s action, and effects that belong to entacapone itself.

On the levodopa side, the most common problem is increased dyskinesia, meaning involuntary twisting or jerking movements that happen when levodopa levels peak. In a six-month German and Austrian trial, dyskinesias were reported in about a third of patients on entacapone versus a quarter on placebo. Nausea was also more common, hitting roughly 10% on entacapone versus 5% on placebo. Both effects were generally manageable by reducing the levodopa dose, and they tended to appear early in treatment.⁸

Constipation and drops in blood pressure upon standing are also reported with entacapone, though these overlap with effects of Parkinson’s disease itself and of levodopa.⁹ If you notice lightheadedness when getting up from a chair, mention it to your neurologist rather than assuming it will pass on its own.

The Orange Urine Effect

One of the most startling but least dangerous effects of entacapone is that it can turn your urine a dark yellow to bright orange color. This has nothing to do with kidney problems or dehydration. It is simply the color of entacapone and its breakdown products being filtered out through the kidneys.¹⁰ The discoloration is harmless and stops when the drug is discontinued. Sweat and other body fluids can also take on a faint brownish tint in some people. This effect is worth knowing about in advance because it causes unnecessary alarm if you are not expecting it.

Diarrhea and Rare Gastrointestinal Complications

Diarrhea is one of the more troublesome side effects, and while it is usually mild, a small number of people develop severe chronic diarrhea that can lead to significant weight loss. In one published case, a 72-year-old man developed watery diarrhea occurring five to six times daily after two years on entacapone, losing 10 kilograms before the cause was identified. Testing revealed a condition called lymphocytic colitis, an inflammation of the colon lining. After stopping entacapone, his diarrhea resolved completely within two weeks and he regained the lost weight.¹¹

This kind of severe reaction is uncommon, but the delay between starting the drug and developing symptoms can make it hard to recognize. If persistent diarrhea develops at any point while you are on entacapone, even months or years after starting, bring it up with your doctor rather than attributing it to something else. In most cases, entacapone-related diarrhea resolves after the drug is stopped.

How Entacapone Compares to Other COMT Inhibitors

Three COMT inhibitors are currently used in Parkinson’s disease: entacapone, tolcapone, and the newer opicapone. They all do fundamentally the same thing, but they differ in potency, dosing convenience, and safety.

Entacapone must be taken with every levodopa dose, which means multiple tablets per day. Opicapone is taken once daily at bedtime, making it more convenient. Tolcapone, the oldest of the three, is taken three times daily regardless of levodopa dosing but carries a risk of serious liver damage that the other two do not share. In terms of raw effectiveness, a network meta-analysis across multiple trials found that opicapone at the 50 mg dose produced a somewhat larger increase in daily on-time compared with entacapone, though both were clearly better than placebo.¹²

Where entacapone stands out is safety. A phase IV study comparing all three drugs found that, after adjusting for how long patients were exposed to each drug, entacapone had significantly fewer total adverse events than either opicapone or tolcapone. It also had significantly fewer serious adverse events than both alternatives.¹³ So the trade-off is real: opicapone is easier to take and may be slightly more effective, but entacapone appears to be the safest option for long-term use. The choice often comes down to how well someone tolerates the pill burden and whether convenience or the safety margin matters more to that individual.

Why Entacapone Does Not Cause the Liver Damage Associated With Tolcapone

Tolcapone was pulled from several markets in the late 1990s after reports of fatal liver failure, and it still requires regular liver-function monitoring wherever it is available. Entacapone, despite working on the same enzyme, has not been linked to that kind of liver toxicity. Researchers have investigated why, and the answer comes down to chemistry.

Modeling studies showed that tolcapone is a significantly more potent disruptor of mitochondria (the energy-producing structures inside liver cells) and achieves higher concentrations in liver tissue than entacapone does. The combination of stronger mitochondrial toxicity and greater liver exposure accounts for the difference.¹⁴ More recent laboratory work pointed to subtle differences in the chemical structure of the two drugs, particularly in how fatty (lipophilic) each molecule is and in a specific chemical group attached to the core ring structure, which determines how aggressively each drug interferes with mitochondrial function.¹⁵ For patients and doctors, the practical upshot is straightforward: entacapone does not require the liver monitoring that tolcapone does.

Cardiovascular Safety and Long-Term Outcomes

Because people with Parkinson’s disease are often older and may have coexisting heart disease, questions about long-term cardiovascular safety matter. A large registry-based study looked at rates of heart attack, stroke, and death among elderly Parkinson’s patients using entacapone compared with those not using it. The results were reassuring: entacapone use was not associated with any increased risk for heart attack, stroke, or all-cause death. In fact, the point estimates for all three outcomes slightly favored entacapone, though the differences were not statistically significant. The findings held regardless of whether patients had diabetes, pre-existing heart disease, or kidney problems, and regardless of how long they had been on the drug.¹⁶

Effects on Quality of Life

Adding an extra hour or so of on-time per day sounds modest on paper, but the impact on daily life can be considerable. Studies measuring quality of life with standardized questionnaires found that patients on entacapone reported improvements not just in movement but also in nonmotor areas like mood, personal relationships, communication, and the sense of stigma associated with visible symptoms.¹⁷ A separate study confirmed that activities of daily living improved significantly with entacapone, though broader quality-of-life questionnaire scores did not always reach statistical significance, suggesting the benefits are most tangible in practical function.¹⁸

Longer-term data has reinforced the picture. A study following patients over time found that entacapone sustained reductions in motor-fluctuation severity and improvements in quality-of-life scores, especially when introduced earlier in the course of motor fluctuations rather than waiting until symptoms become severe.¹⁹

Why Entacapone Is Not Used From the Start of Levodopa Treatment

You might wonder: if entacapone smooths out levodopa delivery, why not start it from day one and potentially prevent wearing off and dyskinesias from ever developing? This was exactly the hypothesis behind a major trial called STRIDE-PD, which compared starting levodopa/carbidopa/entacapone as initial therapy against starting plain levodopa/carbidopa.

The result was the opposite of what was hoped. Patients who started with the triple combination actually developed dyskinesias sooner and at higher rates than those on standard levodopa/carbidopa. At week 134, about 42% of the triple-combination group had developed dyskinesias versus 32% of the standard group. The triple-combination group also ended up receiving higher levodopa-equivalent doses over the course of the study.²⁰ Motor scores and time to wearing off were not significantly different between groups.²¹

The STRIDE-PD outcome did not mean entacapone is harmful when used appropriately. The problem was likely that patients starting on the more potent combination ended up on higher effective levodopa doses from the outset, which itself promotes dyskinesias. The lesson was practical: entacapone works best as a tool added later, when wearing off has become a clinical problem, rather than as a preemptive strategy. This is how most neurologists use it today.

Interactions Worth Knowing About

Entacapone affects the same enzyme system that breaks down certain other drugs containing a catechol structure. Medications like certain asthma drugs (epinephrine, isoprenaline) and norepinephrine can have their effects amplified when COMT is blocked, potentially raising heart rate or blood pressure. Your doctor should be aware of any medications you take that affect the catecholamine system.

Iron supplements are another consideration. Entacapone, like other catechol compounds, can bind to iron in the gut, which may reduce the absorption of both the drug and the iron if taken at the same time. Separating doses by at least two hours is a common practical recommendation. The same logic applies to other mineral supplements that can interact with catechol-containing compounds.

Entacapone should not be used alongside non-selective monoamine oxidase (MAO) inhibitors, which block a different enzyme involved in neurotransmitter breakdown. The combination can lead to dangerous surges in catecholamines. Selective MAO-B inhibitors like selegiline or rasagiline, which are commonly used in Parkinson’s disease, are generally considered safe to use with entacapone, though the combination may increase the risk of dopaminergic side effects like dyskinesia. If you take any antidepressants, especially older tricyclics or MAO inhibitors, your neurologist needs to account for them when prescribing entacapone.

Alcohol does not have a known direct interaction with entacapone, but because both can cause dizziness and drops in blood pressure, the combination can leave you unsteady. Parkinson’s disease itself already increases fall risk, so this is worth taking seriously even if no formal interaction exists on paper.

What Happens When You Stop Entacapone

Entacapone should not be stopped abruptly. Because it enhances levodopa’s effect, suddenly removing it is equivalent to a significant drop in your effective levodopa dose. Symptoms of Parkinson’s disease can return sharply, and in rare cases, a rapid withdrawal resembling neuroleptic malignant syndrome (high fever, muscle rigidity, altered consciousness) has been reported with abrupt discontinuation of dopaminergic therapies. If you and your doctor decide to stop entacapone, the transition typically involves gradually increasing the levodopa dose to compensate, rather than simply dropping the entacapone overnight. This is also relevant during hospitalizations, where Parkinson’s medications are sometimes inadvertently skipped or discontinued by unfamiliar medical teams. If you are heading into a hospital stay, making sure your medication list is clearly communicated is one of the most important things you can do.